Our co-founders, Marie-Joe Dib and Zen Jelenje, will be attending the American Society of Human Genetics (ASHG) Annual Meeting 2026 in Montreal, where they will be presenting our latest research on TMPRSS6.
What can human genetics tell us about the benefits and potential risks of inhibiting TMPRSS6?
Our work examines human genetic evidence for the therapeutic potential of TMPRSS6 inhibition, investigating its potential to reduce liver disease risk while evaluating possible safety liabilities that could shape its development as a therapeutic target.
The findings highlight how human genetics can help inform target validation, assess potential efficacy and safety, and guide the development of genetics-informed therapeutic strategies.
Poster presentation details
- Presenter: Marie-Joe Dib
- Poster board: 8405F, Exhibit Hall
- Date: Friday, October 23, 2026
- Time: 2:30–4:30 pm EDT
- Session: Statistical Genetics and Genetic Epidemiology
We look forward to connecting with researchers, clinicians and industry leaders working in human genetics, liver disease, target validation and genetics-informed drug discovery.